The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats

被引:6
|
作者
Cihan, Yasemin Benderli [1 ]
Arsav, Vedat [2 ]
机构
[1] Kayseri Educ & Res Hosp, Clin Radiat Oncol, Kayseri, Turkey
[2] Kayseri Educ & Res Hosp, Clin Pathol, Kayseri, Turkey
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2014年 / 14卷 / 04期
关键词
heart; fibrosis; radiotherapy; trastuzumab; hormonotherapy; cardiac toxicity; rat; BREAST-CANCER; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; TAMOXIFEN; THERAPY; MORTALITY; RISK;
D O I
10.5152/akd.2014.4736
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This experimental study aims to investigate whether radiotherapy (RT) plus trastuzumab (T) followed by subsequent hormonotherapy increase the cumulative toxic effect on cardiac functions in rats. Methods: A total of 70 Wistar Albino female rats with a mean weight 213 +/- 27 g were randomly divided into equal seven groups. The first group (C) underwent no procedure. The second group (RT) underwent the whole thoracic radiation including heart. The third group (T) was administered T through tail vein alone. The fourth group (RT+T+Tx) was administered T initially and the whole thoracic radiation at two hours, followed by tamoxifen at one week. The fifth group (RT+T+Le) was administered T and then underwent thoracic radiation, followed by letrozole. The sixth group (T+RT+An) was administered T and then underwent thoracic radiation, followed by anastrazole. The seventh group (T+RT+Ex) was administered T and then underwent thoracic radiation, followed by exemestane at one week. Hormonotherapy was administered to the rats in the Group 5, 6 and 7, as indicated in the Group 4. Radiation therapy was administered following T treatment at two hours as a single 12 Gy fraction. After the rats were sedated under anesthesia and sacrificed at 24 weeks, cardiac tissues were removed. Serial sections obtained following paraffin blockage were stained and the ratio of myocardial fibrosis was assessed. According to statistical analyses by the one-way ANOVA test and Tukey HSD test, a significant difference between test components. Results: At the end of the study, no loss and adverse effects were seen in any group. There was a statistically significant difference among atrium, ventricle and aorta (p<0.001). The mean value of fibrosis scores increased in the rats which underwent RT. In the assessment of atrium, a significant difference was found between RT group and RT+T+An group and also T group and RT+T+Fe group (p<0.001). In the assessment of ventricule, a statistically significant difference was observed among RT, RT+T+An and RT+T+Ex. In the assessment of aorta, the scores of RT group was significantly higher than RT+T+An and RT+T+Ex. A statistically significant difference was observed among these groups (p<0.001). Conclusion: Our study results suggested that there was no significant additional cardiotoxicity of adjuvant hormonotherapy following concomitant RT and T treatment, compared to RT in terms of cardiac fibrosis.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 50 条
  • [41] ACUTE TOXICITY OF SUBCUTANEOUSLY ADMINISTERED DEPLETED URANIUM AND THE EFFECTS OF CBMIDA IN THE SIMULATED WOUNDS OF RATS
    Fukuda, Satoshi
    Ikeda, Mizuyo
    Nakamura, Mariko
    Yan, Xueming
    Xie, Yuyuan
    HEALTH PHYSICS, 2009, 96 (04): : 483 - 492
  • [42] Does spironolactone ameliorate trastuzumab-induced cardiac toxicity?
    Yavas, Guler
    Elsurer, Rengin
    Yavas, Cagdas
    Elsurer, Cagdas
    Ata, Ozlem
    MEDICAL HYPOTHESES, 2013, 81 (02) : 231 - 234
  • [43] CARDIAC TOXICITY OF TRASTUZUMAB: EXPERIENCE AT THE GHENT UNIVERSITY HOSPITAL, BELGIUM
    Lamot, C.
    Rottey, S.
    De Backer, T.
    Van Bortel, L.
    Robays, H.
    Van Belle, S.
    Denys, H.
    Cocquyt, V.
    ACTA CLINICA BELGICA, 2010, 65 (05) : 300 - 304
  • [44] Trastuzumab Beyond Progression: Is the Risk of Cardiac Toxicity Really Not Increased?
    Morabito, Alessandro
    Piccirillo, Maria Carmela
    De Maio, Ermelinda
    Di Maio, Massimo
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : E123 - E123
  • [45] Cardiac toxicity associated to trastuzumab treatment in usual clinical practice
    Gallego Page, J. C. Juan Carlos
    Gallego Sanchez, G.
    Gomez Perez, A.
    Salas Nieto, J.
    Portero Portaz, J. J.
    Lafuente Gormaz, C.
    Aguilera Saldana, M.
    Aliaga, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 71 - 71
  • [46] Trastuzumab cardiac toxicity: a problem we put our heart into
    Bregni, Giacomo
    Galli, Giulia
    Gevorgyan, Arpine
    de Braud, Filippo
    Di Cosimo, Serena
    TUMORI JOURNAL, 2016, 102 (01): : 1 - 5
  • [47] Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials
    Sparano, JA
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 20 - 27
  • [48] Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity
    Canale, Maria Laura
    Camerini, Andrea
    Huqi, Alda
    Lilli, Alessio
    Bisceglia, Irma
    Parrini, Iris
    Lestuzzis, Chiara
    Del Meglio, Jacopo
    Donati, Sara
    Venturini, Elio
    Sgambato, Alessandro
    Tarantini, Luigi
    Amoroso, Domenico
    Casolo, Giancarlo
    ANTICANCER RESEARCH, 2019, 39 (10) : 5741 - 5745
  • [49] Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients:: acute toxicity analyses from the French multicentric study
    Belkacemi, Y.
    Gligorov, J.
    Ozsahin, M.
    Marsiglia, H.
    De Lafontan, B.
    Laharie-Mineur, H.
    Aimard, L.
    Antoine, E. -C.
    Cutuli, B.
    Namer, M.
    Azria, D.
    ANNALS OF ONCOLOGY, 2008, 19 (06) : 1110 - 1116
  • [50] The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: A single-institution study
    Caussa, Lucas
    Kirova, Youlia M.
    Gault, Nathalie
    Pierga, Jean-Yves
    Savignoni, Alexia
    Campana, Francois
    Dendale, Remi
    Fourquet, Alain
    Bollet, Marc A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) : 65 - 73